(Q33809527)

29 July 2017

1 reference

title

Possible mechanisms of action and reasons for failure of antiviral therapy in chronic hepatitis C. (English)

1 reference

29 July 2017

1 reference

Thomas HC

1

1 reference

29 July 2017

Török ME

series ordinal

2

1 reference

29 July 2017

Forton DM

series ordinal

3

1 reference

29 July 2017

Taylor-Robinson SD

series ordinal

4

1 reference

29 July 2017

publication date

1 January 1999

1 reference

29 July 2017

published in

Journal of Hepatology

1 reference

29 July 2017

volume

31 Suppl 1

1 reference

29 July 2017

page(s)

152-159

1 reference

Natural history of hepatitis C

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980393-6

7 January 2021

Association between HLA class II genotype and spontaneous clearance of hepatitis C viraemia

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980393-6

7 January 2021

T-lymphocyte response to hepatitis C virus in different clinical courses of infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980393-6

7 January 2021

Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980393-6

7 January 2021

Cytotoxic T lymphocyte response to hepatitis C virus-derived peptides containing the HLA A2.1 binding motif

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980393-6

7 January 2021

Quantitative analysis of the peripheral blood cytotoxic T lymphocyte response in patients with chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980393-6

7 January 2021

Hypervariable region of hepatitis C virus envelope glycoprotein (E2/NS1) in an agammaglobulinemic patient.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980393-6

7 January 2021

Specific detection of hepatitis C virus minus strand RNA in hematopoietic cells

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980393-6

7 January 2021

Management of chronic hepatitis C: clinical audit of biopsy based management algorithm

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980393-6

7 January 2021

Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980393-6

7 January 2021

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980393-6

7 January 2021

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980393-6

7 January 2021

Are all type I human interferons equivalent?

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980393-6

7 January 2021

Different relative activities of human cell-derived interferon-alpha subtypes: IFN-alpha 8 has very high antiviral potency

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980393-6

7 January 2021

Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980393-6

7 January 2021

HLA class I antigens on the hepatocyte membrane during recovery from acute hepatitis B virus infection and during interferon therapy in chronic hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980393-6

7 January 2021

Selective expression of an interleukin-12 receptor component by human T helper 1 cells

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980393-6

7 January 2021

Interleukin-12: potential clinical applications in the treatment of chronic viral hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980393-6

7 January 2021

Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980393-6

7 January 2021

Intrahepatic hepatitis C virus-specific cytotoxic T lymphocyte activity and response to interferon alfa therapy in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980393-6

7 January 2021

Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view. The Multivirc Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980393-6

7 January 2021

Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980393-6

7 January 2021

Therapy of hepatitis C: patients with cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980393-6

7 January 2021

Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. European Concerted Action on Viral Hepatitis (EUROHEP)

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980393-6

7 January 2021

Reduced plasma transforming growth factor-beta1 levels in patients with chronic hepatitis C after interferon-alpha therapy: association with regression of hepatic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980393-6

7 January 2021

Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980393-6

7 January 2021

Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: molecular mechanisms of kinase regulation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980393-6

7 January 2021

Inhibition of tumor necrosis factor (TNF-alpha)-mediated apoptosis by hepatitis C virus core protein

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980393-6

7 January 2021

Hepatitis C virus core protein interacts with the cytoplasmic tail of lymphotoxin-beta receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980393-6

7 January 2021

Suppression of apoptotic cell death by hepatitis C virus core protein

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980393-6

7 January 2021

Ultrarapid hepatitis C virus clearance by daily high-dose interferon in non-responders to standard therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980393-6

7 January 2021

Randomised controlled trial of interferon alfa (lymphoblastoid interferon) in chronic non-A non-B hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980393-6

7 January 2021

Viral dynamics in hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980393-6

7 January 2021

Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980393-6

7 January 2021

1H MR spectroscopy of the brain in HIV-1-seropositive subjects: evidence for diffuse metabolic abnormalities

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980393-6

7 January 2021

The microglial cell. A historical review

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980393-6

7 January 2021

Turnover of resident microglia in the normal adult mouse brain

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980393-6

7 January 2021

Differences in hypervariable region 1 quasispecies of hepatitis C virus in human serum, peripheral blood mononuclear cells, and liver

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980393-6

7 January 2021

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980393-6

7 January 2021

The importance of IMP dehydrogenase inhibition in the broad spectrum antiviral activity of ribavirin and selenazofurin.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980393-6

7 January 2021

Ribavirin uptake by human erythrocytes and the involvement of nitrobenzylthioinosine-sensitive (es)-nucleoside transporters

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980393-6

7 January 2021

Specific interaction of eukaryotic translation initiation factor 3 with the 5' nontranslated regions of hepatitis C virus and classical swine fever virus RNAs

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980393-6

7 January 2021

The antiviral compound ribavirin modulates the T helper (Th) 1/Th2 subset balance in hepatitis B and C virus-specific immune responses

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980393-6

7 January 2021

10.1016/S0168-8278(99)80393-6

Identifiers

DOI

1 reference

29 July 2017

1 reference